AbbVie-backed Stemson snags $15M series A for hairy brush-up with Rogaine, Propecia

AbbVie wants more people to regain the pleasure of going to a barbershop or local hair salon, and the biopharma has a keen eye for aesthetics. So, it's backing Stemson Therapeutics as part of a $15 million series A, disclosed Thursday.